Activation of CD4 cells by fibronectin and anti-CD3 antibody. A synergistic effect mediated by the VLA-5 fibronectin receptor complex

UMMS Affiliation

Department of Medicine, Division of Rheumatology

Publication Date


Document Type



Antibodies, Monoclonal; Antigens, CD29; Antigens, CD3; Antigens, Differentiation; Antigens, Differentiation, T-Lymphocyte; CD4-Positive T-Lymphocytes; Cells, Cultured; Electrophoresis, Gel, Two-Dimensional; Extracellular Matrix; Fibronectins; Humans; In Vitro Techniques; *Lymphocyte Activation; Receptors, Antigen, T-Cell; Receptors, Cytoadhesin; Receptors, Very Late Antigen


Immunology and Infectious Disease | Musculoskeletal Diseases | Rheumatology | Skin and Connective Tissue Diseases


In this study, fibronectin synergized with anti-CD3 antibody to promote CD4 cell proliferation in a serum-free culture system. The cell-adhesive domain plus additional regions of the fibronectin molecule are involved in this synergy. Anti4B4(CDw29) antibody blocked the activation of CD4 cells in this system. Furthermore, it is the VLA-5 protein within the set of molecules recognized by anti-4B4 that serves as a fibronectin receptor on the CD4 lymphocytes. The VLA-5 fibronectin receptor was mainly expressed on CD4+ CD45R-CDw29+ cells and may in part contribute to the unique function of these cells.


J Exp Med. 1989 Oct 1;170(4):1133-48.

Journal/Book/Conference Title

The Journal of experimental medicine


At the time of publication, Jonathan Kay was not yet affiliated with the University of Massachusetts Medical School.

Related Resources

Link to Article in PubMed

PubMed ID